Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Melnick

Showing results (261-270 of 322) with videos related to

Pageof 33
Sort By:
Cell Reports|November 26, 2020
Clonal Hematopoiesis Before, During, and After Human SpaceflightNuria Mencia-Trinchant, Matthew J MacKay, Christopher Chin, et al.
Blood|October 17, 2014
The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemiaJoni Van der Meulen, Viraj Sanghvi, Konstantinos Mavrakis, et al.
The Journal of Experimental Medicine|May 26, 2010
BCL6 is critical for the development of a diverse primary B cell repertoireCihangir Duy, J Jessica Yu, Rahul Nahar, et al.
Blood Neoplasia|April 20, 2026
Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphomaCalixte Calaud, Emilio M Serrano-Lopez, Leonie A Cluse, et al.
Cancer Cell|May 13, 2020
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune ResponseWendy Béguelin, Matt Teater, Cem Meydan, et al.
Nature Immunology|January 12, 2021
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformationMartín A Rivas, Cem Meydan, Christopher R Chin, et al.
Science Translational Medicine|May 30, 2014
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemiaStephen S Chung, Eunhee Kim, Jae H Park, et al.
Blood|October 4, 2018
Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host diseaseKatelyn Paz, Ryan Flynn, Jing Du, et al.
Cancer Cell|December 6, 2024
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell functionYusuke Isshiki, Xi Chen, Matt Teater, et al.
The Journal of Clinical Investigation|August 3, 2016
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphomaMariano G Cardenas, Wenbo Yu, Wendy Beguelin, et al.
Pageof 33

Showing results (261-270 of 322) with videos related to

Sort By:
Pageof 33
Cell Reports|November 26, 2020
Clonal Hematopoiesis Before, During, and After Human SpaceflightNuria Mencia-Trinchant, Matthew J MacKay, Christopher Chin, et al.
Blood|October 17, 2014
The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemiaJoni Van der Meulen, Viraj Sanghvi, Konstantinos Mavrakis, et al.
The Journal of Experimental Medicine|May 26, 2010
BCL6 is critical for the development of a diverse primary B cell repertoireCihangir Duy, J Jessica Yu, Rahul Nahar, et al.
Blood Neoplasia|April 20, 2026
Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphomaCalixte Calaud, Emilio M Serrano-Lopez, Leonie A Cluse, et al.
Cancer Cell|May 13, 2020
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune ResponseWendy Béguelin, Matt Teater, Cem Meydan, et al.
Nature Immunology|January 12, 2021
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformationMartín A Rivas, Cem Meydan, Christopher R Chin, et al.
Science Translational Medicine|May 30, 2014
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemiaStephen S Chung, Eunhee Kim, Jae H Park, et al.
Blood|October 4, 2018
Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host diseaseKatelyn Paz, Ryan Flynn, Jing Du, et al.
Cancer Cell|December 6, 2024
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell functionYusuke Isshiki, Xi Chen, Matt Teater, et al.
The Journal of Clinical Investigation|August 3, 2016
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphomaMariano G Cardenas, Wenbo Yu, Wendy Beguelin, et al.
Pageof 33